LEADER 04641nam 2200685Ia 450 001 9910140803903321 005 20230725024917.0 010 $a1-4443-4766-7 010 $a1-282-77452-2 010 $a9786612774522 010 $a1-4443-1958-2 010 $a1-4443-1653-2 035 $a(CKB)2670000000043803 035 $a(EBL)589168 035 $a(SSID)ssj0000411605 035 $a(PQKBManifestationID)11252318 035 $a(PQKBTitleCode)TC0000411605 035 $a(PQKBWorkID)10357906 035 $a(PQKB)11764668 035 $a(Au-PeEL)EBL589168 035 $a(CaPaEBR)ebr10412449 035 $a(CaONFJC)MIL277452 035 $a(OCoLC)669165509 035 $a(MiAaPQ)EBC589168 035 $a(EXLCZ)992670000000043803 100 $a20090917d2010 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aAlternatives to blood transfusion in transfusion medicine$b[electronic resource] /$fedited by Alice Maniatis, Philippe van der Linden, Jean-Franc?ois Hardy 205 $a2nd ed. 210 $aChichester, West Sussex ;$aHoboken, NJ $cJohn Wiley$d2010 215 $a1 online resource (608 p.) 300 $aRev. ed. of: Transfusion medicine and alternatives to blood transfusion / NATA (Network for Advancement of Transfusion Alternatives). c2000. 311 $a1-4051-6321-6 320 $aIncludes bibliographical references. 327 $aAlternatives to Blood Transfusion in Transfusion Medicine; Contents; Contributors List; Part 1 History and Development of Transfusion Medicine; 1 From Blood Transfusion to Transfusion Medicine; Part 2 Allogeneic Blood Usage-Risks and Benefits; 2 Allogeneic Blood Components; 3 Current Information on the Infectious Risks of Allogeneic Blood Transfusion; 4 Immunological Complications of Blood Transfusion; 5 Immunomodulation and Allogeneic Blood Transfusion; 6 Pathogen Inactivation of Blood Components; 7 The Benefits of Allogeneic Erythrocyte Transfusion: What Evidence Do We Have? 327 $aPart 3 Volume Replacement Section 1 Plasma and Albumin; Section 2 Crystalloids and Synthetic Colloids; Part 4 Tolerance of Anemia; 17 Basic Principles of Oxygen Transport and Calculations; 18 Assessment of Tissue Oxygenation; 19 Tissue Oxygenation and Blood Transfusion; 20 Anemia and Cardiovascular Disease; Part 5 Perioperative Hemostasis; 21 Monitoring of Hemostasis in the Perioperative Setting; 22 Antifibrinolytics in Open-Heart Surgery; 23 Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients; Part 6 Transfusion Triggers 327 $a24 Role of Hemoglobin/Hematocrit 25 Calculation of Blood Loss; 26 Management of Massive Transfusion; Part 7 Alternatives to Allogeneic Blood Transfusion; Section 1 Pharmaceutical Approaches; Section 2 Surgical Techniques; Section 3 Anesthetic Techniques; Section 4 Special Settings; Part 8 Legal and Ethical Issues in Transfusion Medicine; 43 Ethical Aspects of Informed Consent: American Models; 44 Blood Transfusions, Jehovah's Witnesses, and the American Patients' Rights Movement; Part 9 Cost Issues; 45 The Cost and Cost-Effectiveness of Allogeneic and Autologous Blood 327 $a46 Autologous Blood Predonation in Cardiac Surgery 47 Cost-Effectiveness of Pharmacological Alternatives; Index 330 $aMeeting the needs of patients while minimizing blood transfusions requires special expertise, precise monitoring and innovative techniques. This cutting-edge resource covers all the important clinical aspects of transfusion medicine in diverse clinical settings, with a special emphasis on alternatives to transfusion. Edited by a multidisciplinary team consisting of a transfusion specialist, an anesthesiologist and an intensive care specialist this book is endorsed by the Network for Advancement of Transfusion Alternatives. The contributors review the appropriate use of fluids and of blood pr 606 $aBlood$xTransfusion 606 $aBlood$xTransfusion$xComplications 606 $aBlood substitutes$xTherapeutic use 615 0$aBlood$xTransfusion. 615 0$aBlood$xTransfusion$xComplications. 615 0$aBlood substitutes$xTherapeutic use. 676 $a615/.39 701 $aManiatis$b Alice$0889128 701 $aLinden$b Philippe van der$0889129 701 $aHardy$b Jean-Franc?ois$0889130 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910140803903321 996 $aAlternatives to blood transfusion in transfusion medicine$91986589 997 $aUNINA